Literature DB >> 21179035

Toll-like receptor 2 is present in the microenvironment of oral squamous cell carcinoma.

L K Ng1, A M Rich, H M Hussaini, W M Thomson, A L Fisher, L S Horne, G J Seymour.   

Abstract

BACKGROUND: The aim of this study was to investigate the expression of toll-like receptor 2 (TLR2) on cells associated with oral squamous cell carcinoma, epithelial dysplasia and irritative hyperplasia, using immunohistochemistry.
RESULTS: More immune cells expressed TLR2 in carcinoma and dysplasia than in hyperplasia (P<0.001). No hyperplastic samples showed positive TLR2 staining on keratinocytes, whereas keratinocytes in 64% of cases of carcinoma and 74% of cases of dysplasia were TLR2 positive.
CONCLUSION: Positive TLR2 expression in the microenvironment suggests activation of immune surveillance against the altered epithelium, whereas TLR2 expression by malignant keratinocytes may be indicative of resistance to apoptosis as a pro-survival mechanism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21179035      PMCID: PMC3049561          DOI: 10.1038/sj.bjc.6606057

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


The connective tissue adjacent to oral squamous cell carcinoma (OSCC), epithelial dysplasia (ED) and in irritative hyperplasia (IH) is infiltrated by chronic inflammatory cells (CIC) and may exhibit increased vascularity with numerous endothelial cell (EC)-lined vessels. The CIC and EC communicate with other cells in the vicinity through inflammatory mediators and receptors such as toll-like receptors (TLRs). Toll-like receptor 2 is a type I transmembrane protein, which recognises a wide variety of pathogen-associated molecular patterns (PAMPs) from exogenous pathogens, as well as endogenous damage-associated molecular patterns (DAMPs) including heat shock proteins and high-mobility group box 1 protein (HMGB1) (Sato ). Toll-like receptors share a common signalling pathway through myeloid differentiation protein 88, nuclear factor κ-light-chain enhancer of activated B cells (NF-κB) and mitogen-associated protein kinase, eventually leading to the production of type 1 interferon and an immune regulatory response (Akira and Takeda, 2004; Kumagai ). Toll-like receptor expression induces reactive oxygen species and nitrogen intermediates, activates the cytokine network, initiates signal transduction cascades, increases phagocytic efficacy, is associated with maturation of dendritic cells and activates apoptotic pathways (Akira ; Liu, 2006; Wang ). Research relating to TLRs has concentrated primarily on immune cells, but they are also expressed on normal and chronically inflamed epithelial cells of skin and mucosal surfaces (Sato ). Further, some epithelial tumour cells have been shown to express TLRs and this may confer advantage to the tumour cell (Szczepanski , 2009; Sato ). In this study, we investigated TLR2 expression by keratinocytes and other cells in the microenvironment of human OSCC, ED and IH.

Materials and methods

Samples were selected from archival formalin fixed paraffin-embedded tissues accessioned in the Medlab Dental Oral Pathology Diagnostic Service, Faculty of Dentistry, University of Otago. Histological reports were reviewed and tissues from 50 cases of OSCC, 50 white lesions with histological evidence of epithelial dysplasia and 50 oral mucosal hyperplastic lesions were obtained. Human fibrous epulis and tonsillar tissues were used as negative and positive controls. Immunohistochemical staining was performed using a monoclonal mouse antibody against TLR2.1 (sc-21759, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and mouse avidin–biotin complex (sc-2017, Santa Cruz Biotechnology) with a dilution of 1 : 50. The sections were processed manually in the routine manner after being heated with sodium citrate 2.94 g l−1 at 90°C for 10 min for antigen retrieval. A sample known to be positive for TLR2 was included in each run, as was a negative control where the primary antibody was replaced by isotype-matched mouse IgG1 (Santa Cruz Biotechnology, cat: 2025, at 1 μg ml−1 recommended dilution) (Figure 1A). All samples were counterstained with haematoxylin.
Figure 1

Photomicrographs of OSCC isotype control (A) and irritative hyperplasia (B) demonstrating no TLR 2 expression in the epithelium or on inflammatory cells in the connective tissue. The invading epithelial islands of an OSCC demonstrate weakly (C) and strongly (D) positive-TLR 2 expression. Some inflammatory cells in the adjacent fibrous connective tissue show strong positivity in both (C) and (D).

The slides were assessed blind with light microscopy (Olympus BX50; Olympus Corp., Tokyo, Japan), by one of the authors (LKN) who had been trained and calibrated by a specialist oral pathologist (AMR). CIC and EC with dark brown nuclear and cytoplasmic staining visualised at × 200 magnification were classified as being TLR2 positive. Those with pale or no staining were considered negative. Toll-like receptor 2 expression by keratinocytes was categorised into negative, weakly positive (pale brown cytoplasmic staining) or strongly positive (dark brown cytoplasmic staining). Where there was doubt about the intensity of the staining, reference was made to photographs that had been prepared as standards. A standardised methodical microscopic evaluation of the tissue was carried out beginning at one edge of the slide and assessing every second high power field, outlined by a 1 cm square 10 × 10 eyepiece graticule. Examination continued until 1000 CIC and EC in the sub-epithelial connective tissue (IH and ED) and in the connective tissue adjacent to invading epithelial islands (OSCC) were counted. The number of these cells showing positive TLR2 expression was recorded and expressed as a percentage. Toll-like receptor 2 expression by 1000 keratinocytes, in epithelium delineated in the graticule adjacent to the connective tissue, was analysed and the cells were categorised as being negative, weakly positive or strongly positive, as we have previously reported for assessment of other antibodies in oral epithelium (Kerdpon ). The reproducibility of this method was confirmed by all the slides being re-analysed by the first author 4 weeks after the completion of the main assessment and by a selection of slides being counted by another specialist oral pathologist (HMH). Inter-observer correlation was calculated using Pearson's correlation coefficient. Statistical analyses of the experimental data was performed using Mann–Whitney's U-test. A comparison of TLR2 expression between all three tissues and correlation with variables was made using one-way ANOVA and t-test. A probability value below 0.05 was considered statistically significant.

Results

More CIC and EC in the connective tissue of OSCC (19.9%) and ED (16.4%) expressed TLR2 by comparison with those associated with IH (7.5%) (Table 1 and Figure 1). The data were found not to be normally distributed, hence, the mean percentage for each type of tissue was calculated as mean rank (Table 1). Comparisons of mean TLR2 expression in the microenvironment were calculated using the Mann–Whitney's U-test in order to confirm any statistical differences. t-tests and one-way ANOVA confirmed that TLR2 expression in the microenvironment was not affected by patient age, patient gender, site, histological differentiation or by TLR2 expression on lesional keratinocytes. The keratinocytes in IH did not express TLR2 (Figure 1). In contrast, keratinocytes in 64% of OSCC showed weak or strong TLR2 expression, as did 74% of ED (Table 2, Figure 1).
Table 1

Comparison of TLR2 expression in OSCC, ED and IH

Lesion TLR2 mean (%) TLR2 mean rank
OSCC19.993.7
ED16.480.8
IH7.546.5

Abbreviations: ED=epithelial dysplasia; IH=irritative hyperplasia; OSCC=oral squamous cell carcinoma; TLR2=tumour like receptor 2.

OSCC vs IH, P<0.001 (Mann–Whitney's U-test).

ED vs IH, P<0.001 (Mann–Whitney's U-test).

OSCC vs ED, P>0.05 (Mann–Whitney's U-test).

Table 2

Expression of TLR2 by keratinocytes in OSCC, ED and IH

Lesion Negative (%) Weakly positive (%) Strongly positive (%)
OSCC362638
ED264430
IH100

Abbreviations: ED=epithelial dysplasia; IH=irritative hyperplasia; OSCC=oral squamous cell carcinoma.

The inter-observer correlation coefficient was 0.96 (P<0.05), showing significant agreement between the two observers.

Discussion

This study clearly demonstrated higher TLR2 expression on cells in the microenvironment of OSCC and dysplasia as compared with hyperplasia. Toll-like receptor expression on inflammatory cells adjacent to tumour cells has been previously described and has been considered to be beneficial to the host by enhancing maturation of antigen-presenting cells and inhibiting tumour growth (Apetoh ; Szczepanski ). We suggest that another possible mechanism that may contribute to tumour suppression is TLR-induced apoptosis of the altered epithelial cells. The keratinocytes in OSCC and ED have undergone genetic mutations leading to alterations to protein products and/or alterations to chromosome structure (Califano ; Tsui ; Sheu ) and could be perceived as ‘foreign’ by the immune system. This might result in high TLR2 expression by the CIC and EC in the vicinity, as found in this study, and lead to TLR-induced apoptosis in these altered tissues (Huang , 2007; Chen ). Conversely, DAMPS released from injured or necrotic keratinocytes may be recognised by TLRs on immune cells in the microenvironment leading to signals that disrupt the anti-tumour response leading to cancer progression (Lotze ). The DAMP, HMGB1, has been found to be upregulated in some carcinomas in which it activates TLRs, including TLR2, on immune cells and enhances tumour progression (Ellerman ). This study found that 64% of malignant keratinocytes in OSCC and 74% of dysplastic keratinocytes in ED expressed TLR2, but that TLR2 was not expressed on the keratinocytes in the epithelium, which was hyperplastic in response to chronic irritation. To our knowledge, this is the first report demonstrating TLR2 expression on human oral cancer cells and dysplastic oral epithelial cells. Cancer cells from other sites (e.g., melanoma, breast) have been shown to express TLR2, and TLR4 expression has been noted on tumour cells in head and neck squamous cell carcinoma (Goto ; Szczepanski ; Xie ). The expression of TLR2 on malignant keratinocytes suggests that they may be apoptotic resistant, as well as being able to induce apoptosis in targeted immune cells in the vicinity (Chen ; Conroy ; Huang ). These cancer cells appear to have the ability to control the tumour microenvironment to their advantage and influence the immune cells present (Huang ; He ; Chen ), hence, creating a pro-tumour outcome as proposed by Killeen . In conclusion, this study showed that TLR2 was expressed on the keratinocytes of dysplastic epithelium and OSCC. Positive TLR2 expression in the microenvironment suggests that immune surveillance is activated against the altered cells, whereas TLR2 expression by malignant keratinocytes may correlate with apoptosis resistance and, hence, the survival of tumour cells. Now that TLR2-positive cells have been detected in OSCC, this proposition needs to be tested to determine their functional activity in terms of gene expression and cytokine profiling.
  24 in total

1.  TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance.

Authors:  Weigang He; Qiuyan Liu; Li Wang; Wei Chen; Nan Li; Xuetao Cao
Journal:  Mol Immunol       Date:  2007-02-27       Impact factor: 4.407

2.  Assessment of expression of toll-like receptors 2, 3 and 4 in laryngeal carcinoma.

Authors:  Mirosław Szczepański; Maria Stelmachowska; Lukasz Stryczyński; Wojciech Golusiński; Husam Samara; Iwona Mozer-Lisewska; Jan Zeromski
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-12-13       Impact factor: 2.503

3.  Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma.

Authors:  Jim Jinn-Chyuan Sheu; Chun-Hung Hua; Lei Wan; Ying-Ju Lin; Ming-Tsung Lai; Hsien-Chang Tseng; Natini Jinawath; Ming-Hsui Tsai; Nai-Wen Chang; Chin-Fen Lin; Chyi-Chyang Lin; Lie-Jiau Hsieh; Tian-Li Wang; Ie-Ming Shih; Fuu-Jen Tsai
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

4.  Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling.

Authors:  Bo Huang; Jie Zhao; Shiqian Shen; Hongxing Li; Kai-Li He; Guan-Xin Shen; Lloyd Mayer; Jay Unkeless; Dong Li; Ye Yuan; Gui-Mei Zhang; Huabao Xiong; Zuo-Hua Feng
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

Review 5.  Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells.

Authors:  R Chen; A B Alvero; D-A Silasi; K D Steffensen; G Mor
Journal:  Oncogene       Date:  2008-01-07       Impact factor: 9.867

Review 6.  TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours.

Authors:  H Conroy; N A Marshall; K H G Mills
Journal:  Oncogene       Date:  2008-01-07       Impact factor: 9.867

7.  Multiple aberrations of chromosome 3p detected in oral premalignant lesions.

Authors:  Ivy F L Tsui; Miriam P Rosin; Lewei Zhang; Raymond T Ng; Wan L Lam
Journal:  Cancer Prev Res (Phila)       Date:  2008-11

8.  Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack.

Authors:  Miroslaw J Szczepanski; Malgorzata Czystowska; Marta Szajnik; Malgorzata Harasymczuk; Michael Boyiadzis; Aleksandra Kruk-Zagajewska; Witold Szyfter; Jan Zeromski; Theresa L Whiteside
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

9.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

Review 10.  Masquerader: high mobility group box-1 and cancer.

Authors:  Jessica E Ellerman; Charles K Brown; Michael de Vera; Herbert J Zeh; Timothy Billiar; Anna Rubartelli; Michael T Lotze
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

View more
  15 in total

Review 1.  Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis?

Authors:  Li Yu; Liantang Wang; Shangwu Chen
Journal:  Cell Mol Life Sci       Date:  2011-11-03       Impact factor: 9.261

2.  TLR2 deficiency enhances susceptibility to oral carcinogenesis by promoting an inflammatory environment.

Authors:  Bang Li; De-Qiang Hou; Shuang-Bo Xu; Jia-Yi Zhang; Li-Fang Zhu; Qiong Wang; Lu Pan; Miao Yu; Wei-Li Shen; Wei-Wen Zhu; Wei Zhang; Ying-Ming Sun; Lai-Kui Liu
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

3.  Association between Tissue Expression of Toll-Like Receptor and Some Clinicopathological Indices in Oral Squamous Cell Carcinoma.

Authors:  Reza Zare; Kazem Anvari; Farnaz Mohajertehran; Alieh Farshbaf; Atessa Pakfetrat; Amir Houshang Ansari; Maryam Ghelichli; Nooshin Mohtasham
Journal:  Rep Biochem Mol Biol       Date:  2022-07

Review 4.  Toll-like receptors: exploring their potential connection with post-operative infectious complications and cancer recurrence.

Authors:  S D Gowing; J J Cool-Lartigue; J D Spicer; A J E Seely; L E Ferri
Journal:  Clin Exp Metastasis       Date:  2020-01-23       Impact factor: 5.150

5.  Genes and pathways monotonically dysregulated during progression from normal through leukoplakia to gingivo-buccal oral cancer.

Authors:  Debodipta Das; Arindam Maitra; Chinmay K Panda; Sandip Ghose; Bidyut Roy; Rajiv Sarin; Partha P Majumder
Journal:  NPJ Genom Med       Date:  2021-05-12       Impact factor: 8.617

6.  Targeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma.

Authors:  Lovisa Farnebo; Arash Shahangian; Yunqin Lee; June Ho Shin; Ferenc A Scheeren; John B Sunwoo
Journal:  Oncotarget       Date:  2015-04-30

Review 7.  Viral Modulation of TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers.

Authors:  Marconi Rego Barros; Talita Helena Araújo de Oliveira; Cristiane Moutinho Lagos de Melo; Aldo Venuti; Antonio Carlos de Freitas
Journal:  J Immunol Res       Date:  2018-05-02       Impact factor: 4.818

8.  Evaluation of Toll-Like Receptor Expression with Clinicopathologic Variables in Endometrium Cancer.

Authors:  Berat Berrin Gençoğlu Bakbak; Tolgay Tuyan Ilhan; Aybike Pekin; Özlem Seçilmiş Kerimoğlu; Setenay Arzu Yılmaz; Ayşegül Kebapçılar; Nasuh Utku Doğan; Pınar Karabağlı; Çetin Çelik
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2018-09-04

Review 9.  Toll-like receptors and cancer, particularly oral squamous cell carcinoma.

Authors:  Alison Mary Rich; Haizal Mohd Hussaini; Venkata P B Parachuru; Gregory J Seymour
Journal:  Front Immunol       Date:  2014-09-24       Impact factor: 7.561

10.  Crosstalk between the HIF-1 and Toll-like receptor/nuclear factor-κB pathways in the oral squamous cell carcinoma microenvironment.

Authors:  Shengwei Han; Wenguang Xu; Zhiyong Wang; Xiaofeng Qi; Yufeng Wang; Yanhong Ni; Hao Shen; Qingang Hu; Wei Han
Journal:  Oncotarget       Date:  2016-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.